Skip to content

Author

Hongyan Tong

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Efficacy and Safety of NTQ5082 in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria.

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematologic disorder characterized by complement-mediated intravascular hemolysis, pancytopenia, and thrombosis. NTQ5082 is a novel oral selective complement factor B (CFB) inhibitor that suppresses alternative pathway activity, thereby inhibiting intravascular hemo...

Li Zhang, Gai-Xiang Xu, Ling-Hui Xia et al. · 0 citations
Open access Oct 2026

Venetoclax combined with olverembatinib and prednisone as a frontline therapeutic strategy for Philadelphia chromosome-positive mixed-phenotype acute leukemia

Mixed-phenotype acute leukemia (MPAL) is a rare hematological malignancy with poor prognosis, for which there are currently no standardized therapeutic guidelines. Preclinical and clinical studies have shown that venetoclax and BCR::ABL1 tyrosine kinase inhibitors have synergistic effects on Philadelphia chromosome–pos...

Xia Li, Yi-Le Zhou, Xiang-Jie Lin et al. · 0 citations
Review Open access Sep 2026

Megakaryocytes in myelofibrosis: mechanisms of fibrotic niche remodeling and therapeutic implications

Clinical improvement, suppression of abnormal megakaryopoiesis, reduction in profibrotic signaling, and regression of bone marrow fibrosis should be assessed separately using measures matched to each therapeutic mechanism.

Jian-Song Huang, Xiao-Yue Yin, Xiao-Feng Shi et al. · 0 citations
Open access Aug 2026

Sequential therapy with decitabine and an XPO-1 inhibitor followed by allogeneic hematopoietic stem cell transplantation in MDS with biallelic TP53 inactivation patients : a preliminary case series

Myelodysplastic syndrome with biallelic TP53 inactivation (MDS-biTP53) patients represents an ultra-high-risk subgroup with dismal outcomes. Even after allogeneic hematopoietic stem cell transplantation (allo-HSCT), relapse rates remain extremely high and survival is poor. This preliminary case series reports the outco...

Yan-Ling Ren, W. Lang, Yu Xu et al. · 0 citations
Case report Open access Aug 2026

Identification of novel UBE2E3::PDE1A and CTC1::MEF2C fusion transcripts in acute myeloid leukemia

Using mRNA sequencing, two novel fusion genes are identified and validated and it is proposed that the combination of these novel fusion genes, multiple SNVs, and the complex karyotype collectively contributed to the patient’s multidrug resistance.

Jifang Tu, Yungui Wang, Xiangli Gao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.